Virax Biolabs Group Limited
VRAX · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -96% | 1,727.1% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -838.2% | 32.3% | -15.9% | – |
| R&D Expenses | $2 | $2 | $0 | $0 |
| G&A Expenses | $4 | $5 | $5 | $1 |
| SG&A Expenses | $4 | $5 | $5 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $7 | $6 | $2 |
| Operating Income | -$6 | -$6 | -$6 | -$2 |
| % Margin | -97,344.8% | -4,153.3% | -66,963.7% | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$6 | -$7 | -$5 | -$2 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$6 | -$7 | -$5 | -$2 |
| % Margin | -95,739.2% | -4,304.8% | -63,748.3% | – |
| EPS | -1.96 | -3.36 | -5.13 | -1.5 |
| % Growth | 41.7% | 34.5% | -242% | – |
| EPS Diluted | -1.95 | -3.36 | -5.13 | -1.5 |
| Weighted Avg Shares Out | 3 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 3 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $2 |
| EBITDA | -$6 | -$7 | -$5 | -$0 |
| % Margin | -91,649.5% | -4,225.3% | -63,570.7% | – |